News | May 03, 2021
RPG Life Sciences reports Rs. 6.92 crore PAT in Q4 FY2020-21
The company reported total income of Rs.390.05 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.390.05 crores during the 12 months period ended March 31, 2021
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
The country has constantly worked with the spirit of public-private partnership
The merger is in line with Solara’s strategy of accelerating growth via appropriate inorganic actions
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Pharma industry is ready to embrace technology platforms with a keen focus on automation in manufacturing and digital health investment.
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
The company will review FDA's response and decide on appropriate next steps soon.
The company continued to maintain clear FDA status across its plants and has received 12 ANDA approvals during 9MFY21
Subscribe To Our Newsletter & Stay Updated
